Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
December FDA approvals include treatments for weight loss in adolescents, major depressive disorder, lung cancer detection, metastatic non-small cell lung cancer, multiple sclerosis, and lymphoma.
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
If approved, the OTC nasal spray would deliver 4 mg of naloxone per spray.
Recent FDA approvals include treatments for acute low back pain, postoperative nausea and vomiting, multiple myeloma, hemophilia B, and fibromyalgia pain.
Tzield is anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
Amphetamine mixed salts are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Equipment issue may allow someone to break in and cause the pump to deliver too much or too little insulin to the patient.